Lymphocytic leukemia
There are two types of lymphocytic leukemia, one is acute lymphocytic leukemia and the other is chronic lymphocytic leukemia. Acute lymphocytic leukemia is a progressive malignant disease characterized by a large number of immature white blood cells similar to lymphoblasts. These cells can be found in the blood, bone marrow, lymph nodes, spleen and other organs. Chronic lymphocytic leukemia, referred to as CLL, is a malignant proliferative disease of lymphocytes in certain immune-deficient lymphocytes in the lymphocyte system with a slow onset. This disease is rare in my country, accounting for only 3.4% of leukemia, and is more common in Caucasians in Europe and America, accounting for 25-30%. The age of onset is mostly over 50 years old, and it is rare for those under 30 years old. There are more men than women. The main manifestations are systemic lymphadenopathy, splenomegaly, anemia and abnormal increase in lymphocytes in peripheral blood.
Related Drugs
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:
Fujian Nanshaolin Pharmaceutical Co., Ltd.
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:
Shanxi Guorun Pharmaceutical Co., Ltd.
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
Homoharringtonine Sodium Chloride Injection
Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.
Homoharringtonine Sodium Chloride Injection
Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.
Manufacturer:
Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.
Homoharringtonine Sodium Chloride Injection
Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.
Manufacturer:
Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.
Fludarabine Phosphate Tablets
Indication: It is suitable for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have received at least one standard alkylating agent regimen, but whose condition has not improved or continues to progress during or after treatment. Reference: It is used for the treatment of B-cell chronic lymphocytic leukemia (CLL), and is suitable for patients whose condition has not responded to a standard dosing regimen containing alkylating agents or whose condition has worsened, with an overall effective rate of 32% to 48%. Fudahua Tablets (Fludarabine Phosphate Tablets) can also be used to treat leukemia and lymphoma, but it is not effective for solid tumors such as breast cancer, colon cancer, non-small cell lung cancer, and head and neck cancer.